Antithrombotic Therapy in Patients with Recent Stroke and Atrial Fibrillation

Author(s): Bunny Saberwal, Adam Ioannou, Wei Y. Lim, Anne-Marie Beirne, Anthony W. Chow, Dimitris Tousoulis, Syed Ahsan, Nikolaos Papageorgiou*

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 23 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Atrial fibrillation (AF) is a common arrhythmia which carries a significant risk of stroke. Secondary prevention, particularly in the acute phase of stroke with anti-thrombotic therapy, has not been validated. The aim of this review is to evaluate the available evidence on the use of antithrombotic therapy in patients with recent stroke who have AF, and suggest a treatment algorithm for the various time points, taking into account both the bleeding and thrombosis risks posed at each stage.

Keywords: Atrial Fibrillation (AF), acute phase in stroke, anti-thrombotic, anticoagulation, treatment algorithm, arrhythmia.

[1]
Lip GYH, Brechin CM, Lane DA. The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe. Chest 2012; 142(6): 1489-98.
[http://dx.doi.org/10.1378/chest.11-2888] [PMID: 22459778]
[2]
Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014; 129(8): 837-47.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.113.005119] [PMID: 24345399]
[3]
Magnussen C, Niiranen TJ, Ojeda FM, et al. BiomarCaRE Consortium. Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarCaRE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe). Circulation 2017; 136(17): 1588-97.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.028981] [PMID: 29038167]
[4]
Allan V, Honarbakhsh S, Casas JP, et al. Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? A systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants. Thromb Haemost 2017; 117(5): 837-50.
[http://dx.doi.org/10.1160/TH16-11-0825] [PMID: 28229164]
[5]
Wakili R, Voigt N, Kääb S, Dobrev D, Nattel S. Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest 2011; 121(8): 2955-68.
[http://dx.doi.org/10.1172/JCI46315] [PMID: 21804195]
[6]
Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet 2010; 375(9721): 1212-23.
[http://dx.doi.org/10.1016/S0140-6736(10)60096-7] [PMID: 20334907]
[7]
Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 2008; 1(1): 62-73.
[http://dx.doi.org/10.1161/CIRCEP.107.754564] [PMID: 19808395]
[8]
Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997; 96(4): 1180-4.
[http://dx.doi.org/10.1161/01.CIR.96.4.1180] [PMID: 9286947]
[9]
Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339(10): 659-66.
[http://dx.doi.org/10.1056/NEJM199809033391003] [PMID: 9725923]
[10]
de Vos CB, Pisters R, Nieuwlaat R, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol 2010; 55(8): 725-31.
[http://dx.doi.org/10.1016/j.jacc.2009.11.040] [PMID: 20170808]
[11]
Ioannou A, Papageorgiou N, Singer D, Missouris CG. Registry report of the prevalence of ECG abnormalities and their relation to patient characteristics in an asymptomatic population. QJM 2018; 111(12): 875-9.
[http://dx.doi.org/10.1093/qjmed/hcy212] [PMID: 30239921]
[12]
Fang MC, Singer DE, Chang Y, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005; 112(12): 1687-91.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.105.553438] [PMID: 16157766]
[13]
Manning WJ, Silverman DI, Katz SE, et al. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. J Am Coll Cardiol 1994; 23(7): 1535-40.
[http://dx.doi.org/10.1016/0735-1097(94)90652-1] [PMID: 8195510]
[14]
Leung DY, Black IW, Cranney GB, Hopkins AP, Walsh WF. Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. J Am Coll Cardiol 1994; 24(3): 755-62.
[http://dx.doi.org/10.1016/0735-1097(94)90025-6] [PMID: 8077549]
[15]
Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137(2): 263-72.
[http://dx.doi.org/10.1378/chest.09-1584] [PMID: 19762550]
[16]
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138(5): 1093-100.
[http://dx.doi.org/10.1378/chest.10-0134] [PMID: 20299623]
[17]
Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 2007; 109(6): 2285-92.
[http://dx.doi.org/10.1182/blood-2006-01-010645] [PMID: 17148593]
[18]
Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146(12): 857-67.
[http://dx.doi.org/10.7326/0003-4819-146-12-200706190-00007] [PMID: 17577005]
[19]
Connolly SJ, Pogue J, Hart RG, et al. ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360(20): 2066-78.
[http://dx.doi.org/10.1056/NEJMoa0901301] [PMID: 19336502]
[20]
Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107(4): 598-603.
[http://dx.doi.org/10.1161/01.CIR.0000046451.38849.90] [PMID: 12566373]
[21]
Paciaroni M, Agnelli G, Corea F, et al. Early hemorrhagic transformation of brain infarction: rate, predictive factors, and influence on clinical outcome: results of a prospective multicenter study. Stroke 2008; 39(8): 2249-56.
[http://dx.doi.org/10.1161/STROKEAHA.107.510321] [PMID: 18535273]
[22]
von Kummer R, Broderick JP, Campbell BC, et al. The Heidelbergbleeding classification: classification of bleeding events after ischemic stroke and reperfusion therapy. Stroke 2015; 46(10): 2981-6.
[http://dx.doi.org/10.1161/STROKEAHA.115.010049] [PMID: 26330447]
[23]
Powers WJ, Rabinstein AA, Ackerson T, et al. American Heart Association Stroke Council. 2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2018; 49(3): e46-e110.
[http://dx.doi.org/10.1161/STR.0000000000000158] [PMID: 29367334]
[24]
Paciaroni M, Agnelli G, Falocci N, et al. Early Recurrence and Cerebral Bleeding in Patients With Acute Ischemic Stroke and Atrial Fibrillation: Effect of Anticoagulation and Its Timing: The RAF Study. Stroke 2015; 46(8): 2175-82.
[http://dx.doi.org/10.1161/STROKEAHA.115.008891] [PMID: 26130094]
[25]
Wang Y, Wang Y, Zhao X, et al. CHANCE Investigators. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013; 369(1): 11-9.
[http://dx.doi.org/10.1056/NEJMoa1215340] [PMID: 23803136]
[26]
Johnston SC, Easton JD, Farrant M, et al. Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. N Engl J Med 2018; 379(3): 215-25.
[http://dx.doi.org/10.1056/NEJMoa1800410] [PMID: 29766750]
[27]
Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 2000; 31(6): 1240-9.
[http://dx.doi.org/10.1161/01.STR.31.6.1240] [PMID: 10835439]
[28]
Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991; 84(2): 527-39.
[http://dx.doi.org/10.1161/01.CIR.84.2.527] [PMID: 1860198]
[29]
EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342(8882): 1255-62.
[http://dx.doi.org/10.1016/0140-6736(93)92358-Z] [PMID: 7901582]
[30]
Bosch RF, Kirch W, Theuer JD, et al. Atrial fibrillation management, outcomes and predictors of stable disease in daily practice: prospective non-interventional study. Int J Cardiol 2013; 167(3): 750-6.
[http://dx.doi.org/10.1016/j.ijcard.2012.03.053] [PMID: 22475841]
[31]
Ioannou A, Metaxa S, Kassianos G, Missouris CG. Anticoagulation for the prevention of stroke in non-valvular AF in general practice: room for improvement. Drugs Context 2016; 5212295
[http://dx.doi.org/10.7573/dic.212295] [PMID: 27403193]
[32]
Kirchhof P, Ammentorp B, Darius H, et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events--European Registry in Atrial Fibrillation (PREFER in AF). Europace 2014; 16(1): 6-14.
[http://dx.doi.org/10.1093/europace/eut263] [PMID: 24084680]
[33]
Ezekowitz MD, Bridgers SL, James KE, et al. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992; 327(20): 1406-12.
[http://dx.doi.org/10.1056/NEJM199211123272002] [PMID: 1406859]
[34]
Singer DE, Hughes RA, Gress DR, et al. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323(22): 1505-11.
[http://dx.doi.org/10.1056/NEJM199011293232201] [PMID: 2233931]
[35]
Alquwaizani M, Buckley L, Adams C, Fanikos J. Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. Curr Emerg Hosp Med Rep 2013; 1(2): 83-97.
[http://dx.doi.org/10.1007/s40138-013-0014-6] [PMID: 23687625]
[36]
Saxena R, Lewis S, Berge E, Sandercock PA, Koudstaal PJ. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 2001; 32(10): 2333-7.
[http://dx.doi.org/10.1161/hs1001.097093] [PMID: 11588322]
[37]
Berge E, Abdelnoor M, Nakstad PH, Sandset PM. Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. Lancet 2000; 355(9211): 1205-10.
[http://dx.doi.org/10.1016/S0140-6736(00)02085-7] [PMID: 10770301]
[38]
O’Donnell MJ, Berge E, Sandset PM. Are there patients with acute ischemic stroke and atrial fibrillation that benefit from low molecular weight heparin? Stroke 2006; 37(2): 452-5.
[http://dx.doi.org/10.1161/01.STR.0000198887.81948.74] [PMID: 16410483]
[39]
Hart RG, Palacio S, Pearce LA. Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials. Stroke 2002; 33(11): 2722-7.
[http://dx.doi.org/10.1161/01.STR.0000035735.49388.4A] [PMID: 12411668]
[40]
Abdul-Rahim AH, Fulton RL, Frank B, et al. VISTA collaborators. Association of improved outcome in acute ischaemic stroke patients with atrial fibrillation who receive early antithrombotic therapy: analysis from VISTA. Eur J Neurol 2015; 22(7): 1048-55.
[http://dx.doi.org/10.1111/ene.12577] [PMID: 25319957]
[41]
Hallevi H, Albright KC, Martin-Schild S, et al. Anticoagulation after cardioembolic stroke: to bridge or not to bridge? Arch Neurol 2008; 65(9): 1169-73.
[http://dx.doi.org/10.1001/archneur.65.9.noc70105] [PMID: 18625852]
[42]
Kim TH, Kim JY, Mun HS, et al. Heparin bridging in warfarin anticoagulation therapy initiation could increase bleeding in non-valvular atrial fibrillation patients: a multicenter propensity-matched analysis. J Thromb Haemost 2015; 13(2): 182-90.
[http://dx.doi.org/10.1111/jth.12810] [PMID: 25472735]
[43]
Morocutti C, Amabile G, Fattapposta F, et al. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. Stroke 1997; 28(5): 1015-21.
[http://dx.doi.org/10.1161/01.STR.28.5.1015] [PMID: 9158644]
[44]
Saxena R, Koudstaal P. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev 2004; (4): CD000187
[http://dx.doi.org/10.1002/14651858.CD000187.pub2] [PMID: 15494992]
[45]
Kirchhof P, Benussi S, Kotecha D, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37(38): 2893-962.
[http://dx.doi.org/10.1093/eurheartj/ehw210] [PMID: 27567408]
[46]
Steffel J, Verhamme P, Potpara TS, et al. ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. Europace 2018; 20(8): 1231-42.
[http://dx.doi.org/10.1093/europace/euy054] [PMID: 29562331]
[47]
Wein T, Lindsay MP, Côté R, et al. Heart and Stroke Foundation Canadian Stroke Best Practice Committees. Canadian stroke best practice recommendations: Secondary prevention of stroke, sixth edition practice guidelines, update 2017. Int J Stroke 2017; 13(4): 420-43.
[48]
Ahmed N, Steiner T, Caso V, Wahlgren N. ESO-KSU session participants. Recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 13-15 November 2016. Eur Stroke J 2017; 2(2): 95-102.
[http://dx.doi.org/10.1177/2396987317699144] [PMID: 29900406]
[49]
Intercollegiate Stroke Working Party. National clinical guideline for stroke. 2016.Available at: https://www.strok eaudit.org/SupportFiles/Documents/Guidelines/2016-National-Clinical-Guideline-for-Stroke-5t-(1).aspx
[50]
Munn D, Abdul-Rahim AH, Fischer U, Werring DJ, Robinson TG, Dawson J. A survey of opinion: When to start oral anticoagulants in patients with acute ischaemic stroke and atrial fibrillation? Eur Stroke J 2018; 3(4): 355-60.
[http://dx.doi.org/10.1177/2396987318787124] [PMID: 31236483]
[51]
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Rev Esp Cardiol (Engl Ed) 2017; 70(1): 50.
[http://dx.doi.org/10.1016/j.rec.2016.11.033] [PMID: 28038729]
[52]
January CT, Wann LS, Calkins H, et al. AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation. 2019; 140(2): e125-51.
[http://dx.doi.org/10.1161/CIR.0000000000000665] [PMID: 30686041]
[53]
Forslund T, Komen JJ, Andersen M, et al. Improved Stroke Prevention in Atrial Fibrillation After the Introduction of Non-Vitamin K Antagonist Oral Anticoagulants. Stroke 2018; 49(9): 2122-8.
[54]
Anguita Sánchez M, Bertomeu Martínez V, Ruiz Ortiz M, et al. Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study. Rev Española Cardiol 2020; 73(1): 14-20.
[55]
Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol 2014; 6: 213-20.
[56]
Anderson C, Heeley E, Huang Y, et al. RE-LY Dabigatran vs Warfarin AF. N Engl J Med 2013; 368(25): 2355-65.
[http://dx.doi.org/10.1056/NEJMoa1214609] [PMID: 23713578]
[57]
Granger CB, Alexander JH, McMurray JJV, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365(11): 981-92.
[http://dx.doi.org/10.1056/NEJMoa1107039] [PMID: 21870978]
[58]
Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369(22): 2093-104.
[http://dx.doi.org/10.1056/NEJMoa1310907] [PMID: 24251359]
[59]
Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365(10): 883-91.
[http://dx.doi.org/10.1056/NEJMoa1009638] [PMID: 21830957]
[60]
Le Roux P, Pollack CV Jr, Milan M, Schaefer A. Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage. J Neurosurg 2014; 121(845)(Suppl.): 1-20.
[http://dx.doi.org/10.3171/2014.8.paradigm] [PMID: 25081496]
[61]
Haas S, Camm AJ, Bassand J-P, et al. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF Am Heart J . 2019; 213: 35-46.
[62]
Steuber TD, Howard ML, Nisly SA. Direct Oral Anticoagulants in Chronic Liver Disease. Ann Pharmacother 2019; 53(10): 1042-9.
[http://dx.doi.org/10.1177/1060028019841582] [PMID: 30947523]
[63]
Lutz J, Jurk K, Schinzel H. Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. Int J Nephrol Renovasc Dis 2017; 10: 135-43.
[http://dx.doi.org/10.2147/IJNRD.S105771] [PMID: 28652799]
[64]
Paciaroni M, Agnelli G, Caso V, et al. Causes and Risk Factors of Cerebral Ischemic Events in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention. Stroke 2019; 50(8): 2168-74.
[65]
Auer E, Frey S, Kaesmacher J, et al. Stroke severity in patients with preceding direct oral anticoagulant therapy as compared to vitamin K antagonists. J Neurol 2019; 266(9): 2263-72.
[66]
Wilson D, Seiffge DJ, Traenka C, et al. Outcome of intracerebral hemorrhage associated with different oral anticoagulants. Neurology 2017; 88(18): 1693-700.
[http://dx.doi.org/10.1212/WNL.0000000000003886]
[67]
Zapata-Wainberg G, Masjuan J, Quintas S, et al. The neurologist’s approach to cerebral infarct and transient ischaemic attack in patients receiving anticoagulant treatment for non-valvular atrial fibrillation: ANITA-FA study. Eur J Neurol 2019; 26(2): 230-7.
[68]
Diener H-C, Stanford S, Abdul-Rahim A, et al. Anti-thrombotic therapy in patients with atrial fibrillation and intracranial hemorrhage. Expert Rev Neurother 2014; 14(9): 1019-28.
[http://dx.doi.org/10.1586/14737175.2014.945435]
[69]
Seiffge DJ, Kägi G, Michel P, et al. Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage. Ann Neurol 2018; 83(3): 451-9.
[http://dx.doi.org/10.1002/ana.25165]
[70]
Chausson N, Soumah D, Aghasaryan M, Altarcha T, Alecu C, Smadja D. Reversal of Vitamin K Antagonist Therapy Before Thrombolysis for Acute Ischemic Stroke. Stroke 2018; 49(10): 2526-8.
[71]
Monagle S, Eikelboom JW, Ng KH, Bhagirath VC. Clinical implications of reversal agents for direct oral anticoagulants. Future Cardiol 2017; 13(2): 153-9.
[http://dx.doi.org/10.2217/fca-2016-0070]
[72]
Wong JWP, Churilov L, Dowling R, et al. Safety of Endovascular Thrombectomy for Acute Ischaemic Stroke in Anticoagulated Patients Ineligible for Intravenous Thrombolysis. Cerebrovasc Dis 2018; 46(5-6): 193-9.
[http://dx.doi.org/10.1159/000493801]
[73]
Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med 2013; 368(10): 893-903.
[74]
Badhiwala JH, Nassiri F, Alhazzani W, et al. Endovascular Thrombectomy for Acute Ischemic Stroke: JAMA 2015; 314(17): 1832.
[75]
Held C, Hylek EM, Alexander JH, et al. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Eur Heart J 2015; 36(20): 1264-72.
[http://dx.doi.org/10.1093/eurheartj/ehu463]
[76]
Hankey GJ, Stevens SR, Piccini JP, et al. Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban. Stroke 2014; 45(5): 1304--2.
[http://dx.doi.org/10.1161/STROKEAHA.113.004506]
[77]
Wang X, Mondal S, Wang J, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs 2014; 14(2): 147-54.
[http://dx.doi.org/10.1007/s40256-013-0055-y]
[78]
Gerner ST, Huttner HB. Patients on NOACs in the Emergency Room. Curr Neurol Neurosci Rep 2019; 19(7): 40.
[http://dx.doi.org/10.1007/s11910-019-0954-7]
[79]
Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39(16): 1330-93.
[80]
Frontera JA, Lewin JJ III, Rabinstein AA, et al. Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage. Neurocrit Care 2016; 24(1): 6-46.
[81]
Gerner ST, Kuramatsu JB, Sembill JA, et al. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol 2018; 83(1): 186-96.
[http://dx.doi.org/10.1002/ana.25134]
[82]
Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for Dabigatran Reversal - Full Cohort Analysis. N Engl J Med 2017; 377(5): 431-41.
[83]
Green L, Tan J, Antoniou S, et al. Haematological management of major bleeding associated with direct oral anticoagulants - UK experience. Br J Haematol 2019; 185(3): 514-22.
[84]
Connolly SJ, Crowther M, Eikelboom JW, et al. Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med 2019; 380(14): 1326-35.
[85]
Hart RG, Coull BM, Hart D. Early recurrent embolism associated with nonvalvular atrial fibrillation: a retrospective study. Stroke 2019; 14(5): 688-93.
[http://dx.doi.org/10.1161/01.STR.14.5.688]
[86]
Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996; 27(10): 1760-4.
[http://dx.doi.org/10.1161/01.STR.27.10.1760]
[87]
Giaquinto S, Ferrara I, Muscherà R, Pagano G, Nolfe G. The effects of atrial fibrillation on functional recovery in post-stroke patients. Disabil Rehabil 2001; 23(5): 204-8.
[88]
Johnston SC, Elm JJ, Easton JD, et al. Time Course for Benefit and Risk of Clopidogrel and Aspirin after Acute Transient Ischemic Attack and Minor Ischemic Stroke: A Secondary Analysis from the POINT Randomized Trial Circulation 2019; 140(8): 658-64.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.119.040713]
[89]
Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack.. Stroke 2014; 45(7): 2160-236.
[http://dx.doi.org/10.1161/STR.0000000000000024]
[90]
Tan S, Wang D, Liu M, Zhang S, Wu B, Liu B. Frequency and predictors of spontaneous hemorrhagic transformation in ischemic stroke and its association with prognosis. J Neurol 2014; 261(5): 905-12.
[91]
Abdul-Rahim AH, Fulton RL, Frank B, et al. Association of improved outcome in acute ischaemic stroke patients with atrial fibrillation who receive early antithrombotic therapy: analysis from VISTA. Eur J Neurol 2015; 22(7): 1048-55.
[http://dx.doi.org/10.1111/ene.12577]
[92]
Cappellari M, Carletti M, Danese A, Bovi P. Early introduction of direct oral anticoagulants in cardioembolic stroke patients with non-valvular atrial fibrillation. J Thromb Thrombolysis 2016; 42(3): 393-8.
[93]
Shibazaki K, Kimura K, Aoki J, Saji N, Sakai K. Early initiation of new oral anticoagulants in acute stroke and TIA patients with nonvalvular atrial fibrillation. J Neurol Sci 2013; 331(1-2): 90-3.
[94]
Wilson D, Ambler G, Banerjee G, et al. Early versus late anticoagulation for ischaemic stroke associated with atrial fibrillation: multicentre cohort study. J Neurol Neurosurg Psychiatry 2019; 90(3): 320-5.
[95]
Seiffge DJ, Paciaroni M, Wilson D, et al. Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation. Ann Neurol 2019; 85(6): 823-34.
[http://dx.doi.org/10.1002/ana.25489]
[96]
Xu Y, Shoamanesh A, Schulman S, et al. Oral anticoagulant reinitiation following intracerebral hemorrhage in non-valvular atrial fibrillation: Global survey of the practices of neurologists, neurosurgeons and thrombosis experts. Phan TG, editor PLoS One. 2018; 13(1), e0191137


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 23
Year: 2020
Published on: 14 July, 2020
Page: [2715 - 2724]
Pages: 10
DOI: 10.2174/1381612826666200407150307
Price: $65

Article Metrics

PDF: 25
HTML: 3